Potiga's High Discontinuation Rate Doesn't Worry FDA
Executive Summary
Almost one-third of clinical trial patients who were taking the antiepileptic drug Potiga (ezogabine) had to stop due to adverse events, but this will not pose an obstacle to FDA approval of the drug.